Oculis Holding AG (CR5)
XFRA 
Summary
CR5 Chart
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
Oculis NASDAQ: OCS said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication.
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.76 per share a year ago.
Oculis Holding AG (CR5) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oculis Holding AG ever had a stock split?
Oculis Holding AG Profile
| Biotechnology Industry | Healthcare Sector | Riad Sherif CEO | XFRA Exchange | CH1242303498 ISIN |
| CH Country | 49 Employees | - Last Dividend | - Last Split | 2 Mar 2023 IPO Date |
Overview
Oculis Holding AG is a visionary clinical-stage biopharmaceutical company focused on pioneering treatments for eye diseases. Based in Zug, Switzerland, Oculis is dedicated to developing innovative drug candidates designed to address the unmet needs of patients suffering from ophthalmic diseases. Leveraging cutting-edge research and development, the company aims to bring forward novel therapeutic options that can offer significant benefits over existing treatments, with a focus on topical formulations which enhance patient compliance and treatment accessibility.
Products and Services
- OCS-01:
- OCS-02:
- OCS-05:
A leading edge in Oculis' product pipeline is OCS-01, a novel formulation of dexamethasone, prepared using the proprietary Optireach technology aimed at enhancing drug delivery to the eye. Currently, OCS-01 is undergoing Phase 3 clinical trials, targeting diabetic macular edema (DME). This product represents a significant leap forward, proposing a non-invasive treatment option with the potential to drastically improve outcomes for patients battling with DME.
OCS-02 is being developed as a topical biologic treatment for dry eye disease, a condition affecting millions globally, often leading to discomfort and impaired vision. Now in Phase 2b clinical trials, OCS-02 aims to address this prevalent condition by mitigating inflammation, offering a new hope for patients in need of effective and easy-to-administer treatment options.
The exploration of neuroprotection in ophthalmology is embodied in OCS-05, a disease modifying agent focused on curtailing neurological damage. Indications for OCS-05 extend to a spectrum of conditions including glaucoma, dry age-related macular degeneration, diabetic retinopathy, and acute optic neuritis. This investigational agent offers a novel approach by aiming to protect and preserve neural health within the eye, potentially slowing or even reversing disease progression in these conditions.
